Lung Cancer

January 28, 2021 - Atezolizumab demonstrated continued clinically meaningful benefits in overall survival, progression-free survival, overall response rate, and duration of response compared with chemotherapy in patients with PD-L1–high wild-type nonsquamous or squamous non–small cell lung cancer.

January 28, 2021 - Adding BMS-986012, anti–fucosyl-GM1 monoclonal antibody, to nivolumab demonstrated promising results in the treatment of patients with relapsed/refractory small cell lung cancer who did not receive previous checkpoint inhibitor therapy.

January 28, 2021 - Rapid, high, and uniform brain exposure was seen with [11C]osimertinib, followed by a reduction in total brain metastases volume with oral administration of the EGFR TKI in patients with EGFR-mutant non–small cell lung cancer and brain metastases.

January 28, 2021 - NRG1 fusions are detectable in patients with non–small cell lung cancer, providing a rationale to perform larger, retrospective studies assessing therapeutic outcomes in patients with NRG1 fusion–positive tumors and evaluate afatinib in this patient subgroup.

January 28, 2021 - Immuno-oncology therapies provided significant potential health gains for both patients and the population, although age should be taken into account to improve accuracy and avoid bias.

January 28, 2021 — Frontline pembrolizumab continued to demonstrate clinically meaningful improvements in overall survival, overall response rate, and time to progression on next-line therapy compared with platinum-based chemotherapy in patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without sensitizing EGFR or ALK mutations.

January 28, 2021 - Pembrolizumab continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer after more than 5 years of follow-up.

January 28, 2021 - The addition of apatinib to single agent chemotherapy showed promising efficacy and was found to be well tolerated in patients with pretreated advanced small cell lung cancer.

January 28, 2021 - Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision.

January 28, 2021 — Pembrolizumab in combination with chemotherapy continued to show improved overall survival and progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic nonsquamous non–small cell lung cancer.

As new findings emerge in the lung cancer treatment paradigm, innovative strategies have resulted in impressive central nervous system activity and encouraging responses with acceptable tolerability.

Dan Costin, MD, discusses initial considerations in early-stage lung cancer.

Joshua K. Sabari, MD, discusses the role of concurrent plasma- and tissue-based molecular testing in lung cancer.

Joshua K. Sabari, MD, discussed the management of patients with early-stage and metastatic lung cancer, the roles of molecular testing, surgery, staging, and ongoing research efforts in the space.

Naiyer A. Rizvi, MD, discusses the clinical implications of the CheckMate-227 trial examining the use of nivolumab plus ipilimumab in the treatment of patients with non–small cell lung cancer.

Nitin Ohri, MD, discusses the role of chemoradiation therapy in locally advanced non–small cell lung cancer.

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.

Martin E. Gutierrez, MD, discusses some of the most encouraging ongoing clinical trials in metastatic NSCLC.

David Spigel, MD, discusses the future of adjuvant targeted therapy in lung cancer.

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

The sustained overall survival benefit with durvalumab and significant disease-free survival benefit benefit with osimertinib in the adjuvant setting represent major advances in the field of non–small cell lung cancer, fueling research with each modality in localized settings.

Henning Gaissert, MD, discusses the importance of tailoring surgical resection strategies to individual patients with lung cancer.

David Spigel, MD, discusses ongoing research with immunotherapy in early-stage lung cancer.

Balazs Halmos, MD, MS, discusses the emergence of KRAS-targeted therapies in lung cancer.

Expert discuss their expectations for research and drug development in oncology in the new year.